Showing posts with label big bud marijuana. Show all posts
Showing posts with label big bud marijuana. Show all posts

Wednesday, November 11, 2009

Should smoking marijuana be a medical option?

Should smoking marijuana be a medical option?



2009








Rocky Hoveland of Greensboro suffers pain from spine, neck and back injuries.
For a long time, he took prescription painkillers. But the drugs often left him dazed, if not null and void.
Then about 10 years ago, he began using marijuana to treat the pain. He found that it didn't eradicate the pain, but it made it more manageable.
"It keeps me from being in that haze of wanting to sleep all day or feeling hung over all day," he said. The prescription medications "were making me lay down, and I ain't one to lay around."

Hoveland and others like him are pushing for North Carolina to legalize cannabis for medical purposes. And they have become part of a national trend.
In November, Michigan became the 13th state to legalize marijuana for medical purposes.
That popular-vote referendum was just the most recent decision in a long-running debate: whether it should be legal for people to use, grow and sell marijuana for medicinal purposes.
On one side: sick, suffering patients, many of
whom are dying. For at least some of them, cannabis eases symptoms of illness or side effects of treatment.
On the other: a federal government that believes marijuana's benefits are too few and its side effects too risky for the drug to be legalized, even to the highly restricted level of cocaine.
Billy, a Davidson County man who didn't want his full name used , once took the prescription painkiller Dilaudid every day after lingering neck and wrist injuries, experiencing some of the same side effects as Hoveland.
Dilaudid "didn't do much" for the pain, he said. "And I got hateful. My family didn't want to be around me."
Marijuana has helped him, too, he said. "Now I'm up and around, hiking and fishing," he said. "Marijuana focuses my mind away from the pain. I'm still hurting, but it's not that important anymore."
Proponents of legalization in North Carolina are ramping up their efforts.
Representatives of the nonprofit N.C. Cannabis Patient Network have toured the state this winter, meeting with politicians, clergy and medical professionals and airing programs on local public-access TV stations.
On May 2, proponents are scheduled to march in Raleigh on behalf of legalization as part of a global one-day protest called the Million Marijuana March.
"We're looking forward to this becoming legal in this state so people can quit living in fear," said Jean Marlowe, the network's executive director. "We're returning dignity to these patients."
Marlowe, who lives in Polk County, has used marijuana since 1991 to treat muscular dystrophy, rheumatoid arthritis, degenerative disk disease, muscle spasticity and fibromyalgia. She says the authorities leave her alone because she has a letter from her doctor saying she needs medical cannabis.
Before using marijuana, she said, the side effects of her various medications left her practically disabled.
"I spent my time throwing up, dizzy," she said. "I couldn't cognize. I couldn't balance my checkbook. I spent my life in a chair, in the corner, with a trash can."
State Rep. Earl Jones, D-Guilford, introduced a bill in the 2008 legislative session to create a study commission to look at legalizing marijuana for medical purposes in North Carolina. Jones plans to reintroduce his bill this year .
"I think the legislature will do the right thing once they see it will benefit the public and they have been educated," Jones said.
But the U.S. Drug Enforcement Administration remains adamantly opposed to legalizing cannabis even for medical purposes. It continues to prosecute under federal law in some other states for growing and distributing the plants.
l l l
The most comprehensive review of the possible medical benefits of marijuana remains a book-length report, "Marijuana and Medicine," published in 1999 by the Institute of Medicine . The institute is part of the National Academies, agencies that advise the government on medicine and other sciences.
That report, co-authored by a researcher at Wake Forest University Baptist Medical Center, examined marijuana use with respect to five areas:
  • Pain, particularly nerve pain experienced by patients with AIDS and other diseases.
  • Nausea and vomiting, often experienced by chemotherapy patients.
  • Wasting syndrome and loss of appetite, often experienced by AIDS and cancer patients.
  • Neurological symptoms, including muscle spasticity and multiple sclerosis.
  • Glaucoma, excessive pressure in the fluid inside the eye. The condition can cause blindness.
In general, the report found that marijuana, though not a panacea, could help relieve some of these symptoms in at least some patients. In some cases, the report found, marijuana worked as well as or better than accepted treatments.
It also found that smoking treats symptoms such as pain and nausea more quickly and effectively than taking the medicine by mouth.
The report raised concerns about the long-term health effects of smoking marijuana, which, like tobacco, is associated with an increased risk of cancer. Such long-term risks probably don't matter for patients who already are dying, the report noted.
A synthetic form of marijuana's most active ingredient, THC, is available by prescription under the trade name Marinol. But it takes longer to work than inhaled marijuana smoke.
Also, taking cannabis by mouth can get patients "higher" than smoked cannabis - which many patients don't want. When THC is eaten, the liver, which smoking bypasses, breaks the psychoactive elements down into even more potent chemicals.
Another problem with synthetic oral cannabis is that it contains only a few active ingredients, while smoked marijuana contains more than 60.
The combination of those ingredients, not just one, may provide the most medical benefit, says Dr. Wilkie Wilson, director of the DukeLEARN neurological-research program at Duke University, who notes that drug companies are researching that question.
"What you need is something, maybe like an aspirator or an inhaler, that can deliver the drug better than a pill would," said Dr. Steven R. Childers, a professor of physiology and pharmacology at Wake Forest University's Bowman Gray School of Medicine. Childers co-wrote the 1999 Institute of Medicine report.
Wilson, co-author of "Buzzed: The Straight Facts About the Most Used and Abused Drugs from Alcohol to Ecstasy," says some patients prefer smoking because it gives them greater control over their dosage - they can choose to stop, or continue, at any time depending on how much relief they're getting.
***
Childers says the 1999 report's general conclusions remain accurate. Researchers have made some incremental advances, particularly in whether cannabis can ease some symptoms of multiple sclerosis. The nonprofit National Multiple Sclerosis Society is paying for a 10-year study, which began in March.
Also, Swiss researchers found in 2006 that cannabis taken orally can ease muscle spasticity in people with spinal-cord injuries. And after promising findings in rats and mice, Israeli researchers plan human trials to determine whether cannabis may slow or halt memory loss in people with Alzheimer's disease.
But U.S. government-sponsored studies since 1999 have been few and far between. The government grows little marijuana for research and tightly restricts its use. Currently, of 768 drug-related studies sponsored by the National Institute for Drug Abuse and registered at http://www.clinicaltrials.gov/, two pertain to medicinal marijuana.
Besides the possible direct benefits to patients, what are the arguments for legalizing medicinal cannabis?
For one thing, it may help patients for whom other drugs are ineffective or cause intolerable side effects. Its own side effects are relatively minor, the long-term cancer risk aside.
Cannabis is safer than many drugs now on the market. There has never been a documented death attributable to marijuana overdose, Wilson says.
And legalization would bring about standardized dosages and quality, aiding both treatment and research.
Critics argue that the drug is psychologically habit-forming. It can be, but it is less so than alcohol, tobacco and such drugs as heroin, the institute report found.
Some research subjects have reported unpleasant feelings or sensations after taking the drug. And some do not like the "high" that comes with taking the drug. That condition also can make it dangerous to drive or perform other skilled tasks and can hurt judgment and short-term memory.
Wilson points out that these ill effects are particularly dangerous in young people, whose growing brains must absorb not only academic knowledge but also social skills.
There is some evidence the drug can hamper the immune system in some patients.
And marijuana is considered a "gateway" drug - one that could lead to use of more potent and dangerous illegal drugs. The 1999 report found little evidence to support that claim on a pharmacological basis. It also observed that alcohol and tobacco are more widely used gateway drugs, particularly among younger people.
For those reasons and others, federal law classifies marijuana as a Schedule I controlled substance, the most restricted type. Such drugs are defined as having no currently accepted medical use in the U.S., a high potential for abuse, and no accepted safe approaches for use even under medical supervision.
Another Schedule I drug is LSD.
Proponents of medicinal marijuana want it reclassified at least as a Schedule II drug, the most restrictive category for addictive drugs with recognized medical uses. Examples include codeine, the active ingredient in many cough medicines, and the painkiller Dilaudid.
The U.S. Drug Enforcement Administration maintains that marijuana's risks are too great, and its medical benefits too few, to legalize it. Even in some of the 13 states that have legalized medicinal marijuana, DEA agents still arrest people on federal drug charges.
And the government can prosecute doctors who prescribe marijuana. To avoid arrest, doctors often give their patients letters stating that the patient needs marijuana, rather than a prescription.
Proponents of medicinal marijuana also argue that regulating the drug should be a state and local matter, not a federal one.
In 2005, the U.S. Supreme Court ruled in a case called Gonzales v. Raich that the federal government had the right to regulate marijuana even within a single state, as opposed to in interstate commerce.
But a more recent Supreme Court decision suggests that the days of such overarching federal regulation might be numbered.
On Dec. 1, the court refused to hear an appeal from the city of Garden Grove, Calif. That city was defying a state court's order to return marijuana it had seized from a man who had won dismissal of drug charges after he provided a statement from his doctor that he needed marijuana.
Proponents hope that these incremental steps will lead to a day on which no one need fear legal punishment for using medicinal cannabis.
"I'd like us to be united in compassion," Marlowe said. "Living in fear of the government is not what we want for people who are sick and dying."
Wilson says marijuana should be legally distributed through pharmacies just as other drugs are.
"We control amphetamines - my God, we give them to kids for attention-deficit disorder," Wilson said. "Just treat (marijuana) like any other regulated pharmaceutical. I don't see any reason not to do that. I just don't see the reason."
After her tour of the state, Marlowe said she is more hopeful than ever about legal medical marijuana.
"I can smell the finish line," she said. "I'm not going to be a criminal much longer."

Thursday, September 24, 2009

Cannabis Science Updates Progress For Its Phytocannabinoid Pharmaceutical Products To Help Reduce ARDS-Associated Deaths From Both The Avian And Swine

Cannabis Science Updates Progress For Its Phytocannabinoid Pharmaceutical Products To Help Reduce ARDS-Associated Deaths From Both The Avian And Swine Influenza Infections

10:08 AM ET 9/21/09 | BusinessWire

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.

Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated, "After discussing our pharmaceutical products and initiatives with the FDA, Cannabis Science has taken certain steps to meet this potentially urgent situation. Although there is much yet to be done, I am very optimistic that we have an opportunity to have our products available to help meet this challenge."

Dr. Melamede concludes with an outline of Cannabis Science corporate guidance on its FDA procedures: "There are a number of critical capabilities that must be assembled into a cohesive whole. The guiding principle of both our scientific and business operations is that, by using appropriate independent contractors that are experts in their fields, the whole is greater than the sum of its parts.

Most importantly, we want everyone to understand the efficient and effective corporate structure that we are creating with holistic principles in mind. We are assembling teams in all the necessary arenas required for our growth and success. We have an agreement with a successful organic producer to provide us with the raw material. We are establishing a genetic testing facility to insure the production of consistent botanical products, as required for FDA approval, using state of the art procedures. We have identified a CGMP compliant processor who will make an FDA approvable extract for further processing by another qualified and experienced manufacturer, who will produce the final commercial product after FDA approval.

Our compliance team of professionals will oversee all of these activities with their many years of FDA experience. We are extremely pleased with the history and quality of expertise of the team that we are bringing together to face the immediate urgent challenges. We again thank our investors for their confidence in providing us with the necessary resources for this revolutionary undertaking. We have a number of exciting new initiatives we plan to announce shortly and we feel honored to be commissioned to make this happen."

H1N1 Swine Flu:

According to the CDC (http://www.cdc.gov/flu/avian/) the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while thus far causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.

Cannabis Science H1N1 Swine Flu Formulation:

We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its pharmaceutical products with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

SOURCE: Cannabis Science Inc.

Sunday, September 20, 2009

Cannabis Science to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medicines.

SOURCE: Cannabis Science, Inc. / marketwire.com

Jul 27, 2009 13:23 ETCannabis Science to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medicines in Treatment of H1N1 Swine Flu as AP Report Predicts Swine Flu Could Hit up to 40 Percent in the USA
SAN FRANCISCO, CA--(Marketwire - July 27, 2009) - Cannabis Science, Inc. (OTCBB:
CBIS), an emerging pharmaceutical cannabis company, is pleased to report that it is moving as fast as possible to assist in the fight against the threat of a deadly influenza pandemic. In conjunction with its recent re-organization, the Company has begun discussions with the FDA as its program moves forward to provide FDA approved solutions for several critical illnesses.

H1N1 Swine Flu:

According to the CDC (
http://www.cdc.gov/flu/avian/) the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.

Cannabis Science H1N1 Swine Flu Formulation:

We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its cannabis extract lozenge with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.

Dr. Robert Melamede, Ph.D., Cannabis Science, Inc., President and CEO, believes there is enormous potential value for cannabinoids to naturally reduce excessive inflammatory immune responses, and the Cannabis Science lozenge formulation could reduce the mortality rate and allow infected individuals to develop a strong natural immunity upon recovery. Dr. Melamede is the former Chairman (ret) of the Biology Department at the University of Colorado (Colorado Springs.)

Dr. Melamede added, "Again, we recommend, based on sound scientific principles, that medical marijuana users should switch to edibles if they come down with an influenza infection. We believe that the irritation associated with the pulmonary route, when a person has an influenza infection, may lead to unnecessary deaths. In contrast, oral administration may prevent many deaths. We hope that due to the magnitude of this pandemic threat, that the FDA will fast track our proposal."

FDA's three rapid special drug release programs:

Fast Track, Accelerated Approval and Priority Review are approaches that are intended to make therapeutically important drugs available at an earlier time. They do not compromise the standards for the safety and effectiveness of the drugs that become available through this process. These revitalized FDA drug review approaches have yielded tangible results in bringing safe and effective drugs to patients with serious diseases more quickly. For example, since 1996, 68 drugs for cancer therapies have received priority review and approval. The FDA reviewed Gleevec, a treatment for chronic myeloid leukemia, in four months. Shortened review times have also brought promising treatments to patients with HIV/AIDS more quickly. Kaletra for the treatment of HIV/AIDS was reviewed and approved in 3.5 months. Pegasys, a combination product for the treatment of Hepatitis C, was approved for marketing in 4 months.

Fast Track, Accelerated Approval, and Priority Review have evolved over time. The FDA has been vigilant in assuring that reducing the time necessary for drug development has not compromised the safety and effectiveness of drugs for patients with serious diseases. The median time required to review a priority review drug was reduced from 13.9 months to 6.7 months.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Thursday, September 17, 2009

Thursday, September 10, 2009

You Might Be A Stoner IF....



Legal Bud

1. you might be a stoner if.... you wear sun glasses at night so you can see better

2 you might be a stoner if.... you have acctually put out a fire with bong water

3 you might be a stoner if.... the term "hydro" does not mean water

4 you might be a stoner if.... you have an usual parking space outside your local head shop

5 you might be a stoner if.... you have a name for your 3 bongs 2 pipes one of which was made by you

6 you might be a stoner if.... you know your measurements from grams to ounces by heart



Legal Bud

7 you might be a stoner if.... your best friends are your dealer and your roller

8 you might be a stoner if.... you sell your car for gas money

9 you might be a stoner if.... after reading this list you have done most if not all

10 you might be a stoner if.... if you respect 4:20 to a religious value

11 you might be a stoner if.... if you sue your employer for not getting holiday pay on april 20th

12 you might be a stoner if.... if glass blowing was your minor and herbology was your major.....please e-mail me we need to chat



Legal Bud

Friday, September 4, 2009

Marijuana Impairs Immune System Functioning

Exposing Marijuana Myths: A Review of the Scientific Evidence




Marijuana Impairs Immune System Functioning




It has been widely claimed that marijuana substantially increases users' risk of contracting various infectious diseases. First emerging in the 1970s, this claim took on new significance in the 1980s, following reports of marijuana use by people suffering from AIDS.


The Facts


The principal study fueling the original claim of immune impairment involved preparations created with white blood cells that had been removed from marijuana smokers and controls. After exposing the cells to known immune activators, researchers reported a lower rate of "transformation" in those taken from marijuana smokers. 26


However, numerous groups of scientists, using similar techniques, have failed to confirm this original study. 27


In fact, a 1988 study demonstrated an increase in responsiveness when white blood cells from marijuana smokers were exposed to immunological activators. 28


Studies involving laboratory animals have shown immune impairment following administration of THC, but only with the use of extremely high doses. For example, one study demonstrated an increase in herpes infection in rodents given doses of 100 mg/kg/day - a dose approximately 1000 times the dose necessary to produce a psychoactive effect in humans. 29


There have been no clinical or epidemiological studies showing an increase in bacterial, viral, or parasitic infection among human marijuana users. In three large field studies conducted in the 1970s, in Jamaica, Costa Rica and Greece, researchers found no differences in disease susceptibility between marijuana users and matched controls. 30


Marijuana use does not increase the risk of HIV infection; nor does it increase the onset or intensity of symptoms among AIDS patients. 31 In fact, the FDA decision to approve the use of Marinol (synthetic THC) for use in HIV-wasting syndrome relied upon the absence of any immunopathology due to THC. 32


Today, thousands of people with AIDS are smoking marijuana daily to combat nausea and increase appetite. There is no scientific basis for claims that this practice compromises their immune responses. Indeed, the recent discovery of a peripheral cannabinoid receptor associated with lymphatic tissue should encourage aggressive exploration of THC's potential use as an immune-system stimulant. 33

Link to begining of Common Marijuana Myths
legalbuds.com
Business Affiliate ProgramsCouponPersonalsAdvertisingShopping